UNC1215 (UNC-1215) is a potent and selective antagonist of L3MBTL3, a member of the MBT (malignant brain tumor) family of methyllysine (Kme) reading domain, with potential antineoplastic activity.

UNC0321 (UNC-0321) is a novel, potent and selective G9a histone methyltransferase inhibitor with anticancer activity.

Valemetostat (formerly known as DS-3201; DS-3201b; Ezharmia) is a first-in-class, investigational and oral EZH1/2 dual inhibitor with anticancer activity.

EI1 (KB-145943; EI-1) is a potent and selective inhibitor of EZH2 (Enhancer of zeste homolog 2) with potential antitumor activity.

A-196 (A196) is a potent, selective and first-in-class inhibitor of SUV420H1 and SUV420H2 (IC50= 25 and 144 nM) with anticancer activity.

PFI-2 HCl, the hydrochloride salt of PFI-2, is a selective, and cell-active lysine methyltransferase SETD7 inhibitor with potential antitumor activity.

LLY-507 (LLY507) is a novel, potent, cell-permeable/active and selective inhibitor of protein-lysine methyltransferase SMYD2 (SET And MYND Domain Containing 2) with potential anticancer activity.

Lirametostat (CPI-1205; CPI 1205, CPI1205) is an orally bioavailable and selective inhibitor of EZH2 (enhancer of zeste homologue 2, a histone lysine methyltransferase) with potential antitumor activity.

A-366 (A366) is a novel, potent and peptide-competitive inhibitor of the histone methyltransferase G9a with anticancer activity.

BRD4770 (BRD-4770) is a novel and selective inhibitor of G9a (a histone methyltransferase, also known as euchromatin histone methyltransferase 2 (EHMT2)) with anticancer activity.